Skip to main content
Sign In
 

Publications


 

Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.

Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson GL, Graham DK.

Oncogene. 2006 Oct 5;25(45):6092-100. Epub 2006 May 1

http://www.ncbi.nlm.nih.gov/sites/entrez/16652142

 

Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.

Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS.

Clin Cancer Res. 2006 May 1;12(9):2662-9.

http://www.ncbi.nlm.nih.gov/sites/entrez/16675557

 

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Linger RM, Keating AK, Earp HS, Graham DK.

Adv Cancer Res. 2008;100:35-83.

http://www.ncbi.nlm.nih.gov/sites/entrez/18620092

 

Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress.

Anwar A, Keating AK, Joung D, Sather S, Kim GK, Sawczyn KK, Brandão L, Henson PM, Graham DK.

J Leukoc Biol. 2009 Jul;86(1):73-9. Epub 2009 Apr 22.

http://www.ncbi.nlm.nih.gov/sites/entrez/19386698

 

Inhibition of Mer and Axl Receptor Tyrosine Kinases Reduces Astrocytoma Cell Growth and Increases Chemosensitivity.

Keating AK, Kim GK, Donson A, Ware K, Salzberg DB, Foreman N, Liang X, Graham DK.

Molecular Cancer Therapeutics, Manuscript under Revision.

 

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK

Blood. 2009 Sep 24;114(13):2678-87. Epub 2009 Jul 30.

http://www.ncbi.nlm.nih.gov/sites/entrez/19643988

 

Patents:

Graham, D.K., Linger R., DeRyckere, D., Sather, S., Keating, A.K., Kim, G., Brandao, L.  Methods and compounds for enhancing anti-cancer therapy. Provisional patent filed 7/29/08.

 

Websites:

Keating, A.K., Linger, R.M.A., Graham, D.K. . MERTK (c-mer proto-oncogene tyrosine kinase). Atlas Genet Cytogenet Oncol Haematol. November 2008 .

 

Abstracts:

Salzberg DB, Keating, AK, Cao J, Sather S, Hill K, Anwar A, and DK Graham.  2004.  Ectopic expression of Mer receptor tyrosine kinase in childhood T-cell acute lymphoblastic leukemia.  Blood 104:162B. (abstract)

 

Keating A.K., Sather S., Donson A., Straessle J., Cao J., Foreman N., Graham D.K.  2005.  et al: Expression of Mer and Axl receptor tyrosine kinase in pediatric astrocytoma patients. J Clin Oncol 23:127s. (suppl, abstr1555)

 

Salzberg, D.B., Keating, A.K., Cao, J., Sather, S. and D.K. Graham.  2005.  The role of Mer receptor tyrosine kinase in pediatric T cell lymphoblastic leukemia.  PAS 57:494. (abstract)

 

Keating A.K., Sather S., Donson A., Straessle J., Cao J., Foreman N., Graham D.K.  2006.  The Aberrant Expression of Mer Receptor Tyrosine Kinase in Pediatric Astrocytomas. Pediatr Blood Cancer, 46:692 (abstract).

 

Linger, R., DeRyckere, D., Brandao, Luis, Sawczyn, K., Keating, A.K., Graham, D.K. 2008.  Synergistic Killing of E2A-PBX1+ B-ALL Cells by Chemotherapeutic Agents and MerTK Inhibition.  Blood 112:982.

 

Keating A.K., Kim, G.K., Donson A., Foreman N., Graham D.K.  2009.  Inhibition of Mer and Axl tyrosine kinase as a novel therapeutic approach to astrocytic tumors. Proceedings of the AACR. (abstract)